AIDS, TRIPS and 'TRIPS plus': The case for developing and less developed countries

Intellectual Property Rights: Innovation, Governance and the Institutional Environment

Volumn , Issue , 2006, Pages 70-106

  Orsi, Fabienne ^a   Camara, Mamadou ^a   Coriat, Benjamin ^a  

^a UNIVERSITÉ PARIS 13   (France)

Author keywords

Generic drugs; IPR; Public Health; Sub Saharan countries; WTO

Indexed keywords

EID: 33845713141     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (33)

1. Arrow, K. (1982), 'Economic welfare and allocation of resources for inventions', in R.R. Nelson (ed.) The Rate and Direction of Inventure Activity, Princeton, NJ: Princeton University Press.
2. Attaran, A. and Gillespie-White, L. (2001), 'Do patents for antiretroviral drugs constrain access to AIDS treatment in Africa?' JAMA, 286, pp. 1886-2001.
3. Bansee, L., Zigani, W. and Traoré, V. (2003), 'Expérience de la CAMEG du Burkina Faso dans la distribution des antirétroviraux', available at www.remed.org/ZIGANI.rtf.
4. Boulet, P. and Forte, G.B. (2000), Les brevets de médicaments dans les pays d'Afrique francophone, report of the joint Mission MSF-WHO-ONUSIDA, available at http://www.accessmed-msf.org.
5. Camara, M. (2003), Le difficile accès des pays d'Afrique Francophone aux ARV: l'exemple du Burkina Faso, mission report, CEPN-IIDE, November.
6. Conseil National de Lutte contre le SIDA (2003), Plan stratégique 2002-2006 de lutte contre le SIDA, Republic of Senegal.
7. Coriat, B. and Orsi, F. (2002), 'Establishing a new regime of intellectual property rights in the United States: origins, content and problems', Research Policy, 32, pp. 1491-507.
8. Coriat, B. and Orsi, F. (2003), 'Brevets pharmaceutiques, génériques et santé publique: le cas de l'accès aux traitements antirétroviraux', Revue d'Economie Publique, Etudes et Recherches, 12, pp. 153-77.
9. Corréa, C. (1999), Intellectual property rights and the use of compulsory licenses: options for developing countries, Geneva: South Centre.
10. Dégui, H. (2002), 'Les limites du programme ACCESS, l'exemple du Gabon', Remed, no. 26, pp. 4-5, available at http://www.remed.org/remed262.pdf.
11. Dumoulin, J. and Maville, G. (1999), 'Prix et accès aux ARV dans les pays du sud: que peuvent faire la communauté internationale et les laboratoires pharmaceutiques', Réseau Médicaments et Développement, No. 22, available at http://www.remed.org/campagne_Medicaments.rtf.
12. Guennif, S. and M'Fuka, C. (2003), 'Impact of intellectual property rights on AIDS public health policy in Thailand' in J.P. Moatti, B. Coriat, Y. Souteyrand, T. Barnett, J. Dumoulin and Y.A. Flori (eds) Economics of AIDS and Access to HIV Care in Developing Countries: Issues and Challenges, ANRS editions, pp. 137-49.
13. Jourdain, R. (2002), 'Les droits de la propriété intellectuelle et la santé publique dans l'Accord de Bangui révisé: défis majeurs en santé publique pour les pays africains', in Commerce, PI & Développement Durable vus de l'Afrique, ICTSD, Enda, Solagral, pp. 106-13.
14. Love, J. (2002), 'Comment on the Attaran/Gillespie-White and pharma surveys of patents on antiretroviral drugs in Africa' available at www.cptech.org/ip/health/africa/dopatentsmatterinafrica.html.
15. Lucchini, S., Cisse, B., Duran, S., Cenival, M. de, Corniti, C., Gaudry, M. and Moatti, J.-P. (2003), 'Decrease in prices of antiretroviral drugs for developing countries: from political 'philanthropy' to regulated markets?', in J.P. Moatti, B. Coriat, Y. Souteyrand, T. Barnett, J. Dumoulin and Y.A. Flori (eds) Economics of AIDS and Access to HIV Care in Developing Countries: Issues and Challenges, ANRS editions, pp. 169-211.
16. Médecins Sans Frontières (2003a), Untangling the web of price reduction: a pricing guide for the purchase of ARVs for developing countries, 3rd edition, available at: www.accessmed-msf.org.
17. Médecins Sans Frontières (2003b), Drugs patents under the spotlight, available at www.accessmed-msf.org.
18. Médecins Sans Frontières (2004), Deux comprimés par jour pour sauver des vies: combinaisons à dose fixe de médicaments, available at www.accessmed-msf.org.
19. Moatti, J.P., Coriat, B., Souteyrand, Y., Barnett, T., Dumoulin, J. and Flori, Y.A. (eds) (2003), Economics of AIDS and Access to HIV Care in Developing Countries: Issues and Challenges: ANRS editions.
20. Orsi, F. (2002), 'La constitution d'un nouveau droit de propriété intellectuelle sur le vivant aux Etats-Unis: origine et signification économique d'un dépassement de frontière', Revue d'Economie Industrielle, no. 99, 2nd trimester, pp. 65-86. (Special Issue on 'Intellectual Property Rights' coordinated by Benjamin Coriat.)
21. Orsi, F., Hasenclever, L., Fialho, B., Tigre, P., Coriat, B. (2003), 'Intellectual property rights, anti-AIDS policy and generic drugs: lesson from the Brazilian public health program', in J.P. Moatti, B. Coriat, Y. Souteyrand, T, Barnett, J. Dumoulin and Y.A. Flori (eds) Economics of AIDS and Access to HIV Care in Developing Countries: Issues and Challenges. ANRS editions, pp. 109-35.
22. Pammoli, F., Magazzini, L. and Orsenigi, L. (2002), 'The intensity of competition after patent expiry in pharmaceuticals: a cross country analysis', Revue d'Economie Industrielle, no. 99, 2nd trimester, pp. 107-32. (Special Issue on 'Intellectual Property Rights' coordinated by Benjamin Coriat.)
23. Reichman, J. and Hasenzahl, C. (2002), Non-voluntary licensing of patented inventions: historical perspective, legal framework under TRIPS, and an overview of the practice in Canada and the United States of America, UNCTAD/ICTSD.
24. Reichman, J. and Lange, D. (2000), 'Bargaining around the TRIPS Agreement: the case for ongoing public-private initiatives to facilitate worldwide intellectual property transactions', Duke Journal of Comparative and International Law, 9 (11), pp. 11-68.
25. Remiche, B. and Desterbecq, R. (1996), 'Les brevets pharmaceutiques dans les Accords du GATT: l'enjeu?', Revue Internationale de Droit Economique, 1, pp. 7-68.
26. Scherer, F.M. (1993), 'Pricing, profits and technological progress in the pharmaceutical industry', Journal of Economic Perspectives, 7 (3), pp. 97-115.
27. Scherer, F.M. and Watal, J. (2001), Post-TRIPS option for access to patented medicines in developing countries, World Health Organization, Commission on Macroeconomics and Health, CMH Working Paper Series, no. WG4: 1.
28. Tankoano, A. (2002), 'Les importations parallèles et les licences non volontaires dans le nouveau droit des brevets des Etats membres de l'OAPI', in Commerce, PI & Développement Durable vus de l'Afrique, ICTSD, Enda, Solagral, pp. 115-23.
29. t'Hoen, E. (2003), 'TRIPS, pharmaceutical patents and access to essential medicines: Seattle, Doha and beyond', in J.P. Moatti, B. Coriat, Y. Souteyrand, T. Barnett, J. Dumoulin and Y.A. Flori (eds) Economics of AIDS and Access to HIV Care in Developing Countries: Issues and Challenges, ANRS editions, pp. 39-67.
30. UNAIDS (2003), Report on the global AIDS epidemic, available at www.unaids.org.
31. World Health Organization (2004a), Scaling up antiretroviral therapy in resourcelimited settings: Treatment guidelines for a public health approach 2003, Revised version, available at www.who.org.
32. World Health Organization (2004b), Pilot procurement, quality and sourcing project: access to HIV/AIDS drugs and diagnostics of acceptable quality, 14th edition, 28 April 2004, available at www.who.org.
33. Zhang, S. (1994), De l'OMPI au GATT - La protection internationale des droits de propriété intellectuelle, Paris: ITEC.